Home
Search

Letters, Testimony & Comments

BIO submits letters, testimony, and comments to government and regulatory bodies throughout the United States and around the world.

Featured Letters, Testimony, & Comments
CSBA Letter to Congressional Leaders on PBM, PPRV…
Dear Congressional Leaders:On behalf of the Council of State Bioscience Associations (CSBA)—a national coalition of independent, state and territory-based organizations representing the full breadth of America’s biotechnology ecosystem—we write to…
Learn more
BIO's Comments on Advisory Committee on…
Re: Docket No. CDC-2025-0783; Advisory Committee on Immunization Practices (ACIP) MeetingDear Dr. Zadeh and Members of the ACIP:The Biotechnology Innovation Organization (BIO) appreciates the opportunity to provide comments to the Advisory Committee…
Learn more
Testimony of BIO President & CEO John F. Crowley…
Chairman Cassidy, Ranking Member Sanders, and distinguished Members of the Committee:Thank you for the opportunity to appear before you today on behalf of the Biotechnology Innovation Organization (BIO), which represents more than 1,000…
Learn more
All Letters, Testimony & Comments
  • Show All
Search
Results
Questions for the District of Columbia Board of Pharmacy for the drafting of SafeRx
March 10, 2016
Frequently Asked Questions Document
Letter to Governor Deval Patrick
March 10, 2016
BIO letter to Governor Deval Patrick of Massachusetts regarding concerns about Senate Bill 2863.
BIO Testimony regarding Oregan Senate Bill 570
March 10, 2016
Testimony to the Oregon Senate Environment & Land Use Committee regarding The Oregon Genetically Engineered Pharmaceutical and Industrial Crop Act.
Clinical Trials: ICTRP guidelines
March 10, 2016
BIO urges the ICTRP to focus on developing a procedure that would address the need to balance the incentive to innovate with the need to provide patients and health care providers with the information they need in order to assess the availability…
Clinical Trials: Review of the Declaration of Helsinki
March 10, 2016
BIO’s comments on the World Medical Association’s (WMA’s) Declaration of Helsinki.
Request for Comment Extension RE: Docket No. APHIS-2014-0054 – Environmental Impact Statement; Introduction of the Products of Biotechnology
February 18, 2016
We, the undersigned organizations, appreciate the opportunity to provide comment on APHIS’ Notice of Intent (NOI) to prepare an environmental impact statement in connection with potential changes to APHIS biotechnology regulations (7 CFR 340). Our…
BIO 2016 Special 301 Submission
February 8, 2016
The Biotechnology Innovation Organization (BIO) appreciates the opportunity to comment on the 2016 Special 301 Submission. 
BIO Comments on FDA voluntary labeling of GE salmon
January 26, 2016
Food and Drug Administration Docket No. FDA-2015-D-4272; Food Labeling; Voluntary Labeling Indicating Whether Food Has or Has Not Been Derived From Genetically Engineered Atlantic Salmon; Draft Guidance for Industry.
Congressional Black Caucus Letter to EPA on RFS RVO
October 30, 2015
As you finalize the proposed rules under the Renewable Fuel Standard, we respectfully urge you to not reduce the biofuels volume requirements. The RFS program has helped the environment, our economy, and has increased our confidence in renewable…
BIO Submits Comments Re: FDA Rare Diseases Guidance
October 22, 2015
RE: Docket No. FDA–2015–D–2818 Draft Guidance for Industry: Rare Diseases—Common Issues in Drug Development Dear Sir/Madam: The Biotechnology Industry Organization (BIO) appreciates the opportunity to provide feedback in response to the…